Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Hookipa Biotech
Hookipa Biotech
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery
The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
ISPE announces 2024 Facility of the Year Awards category winners
The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Drug Delivery
Hookipa achieves $10 million towards immunotherapy for KRAS-mutated cancers
“We’re excited to advance the HB-700 program, our third in oncology, and we’re eager to explore the potential of our technology in addressing another unmet need in cancer.”
Regulatory
FDA accepts HOOKIPA’s IND application for HB-300 for the treatment of metastatic castration-resistant prostate cancer
Novel arenaviral immunotherapy is directed against the prostate cancer targets PAP and PSA; Phase I/II trial to commence by early 2023
Research & Development
Hookipa and Gilead amend HIV immunotherapy agreement
Under the original agreement, Gilead would assume rights for further development following a joint research phase
Research & Development
Hookipa announces clinical collaboration with Merck USA
The collaboration will evaluate the combination of Hookipa’s arenaviral immunotherapeutic, and Merck’s Keytruda as treatment for patients with advanced head and neck squamous cell carcinoma
Research & Development
Hookipa Gilead collaboration reaches major milestones
The license agreement to focus on HBV and HIV has now delivered 24 research-grade vectors
Recruitment
Dr Jan van de Winkel joins Hookipa as Chairman of its Board of Directors
Reinhard Kandera appointed CFO of Hookipa Biotech
Subscribe now